Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease

NCT04865770 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04865770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04865770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
April 28, 2021
Completion date
November 21, 2024
Enrollment
106 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, diabetes mellitus, type 2